Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update 04 November
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call 28 October
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment 19 October
